NCT02647437Completed
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia
Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia
Source: ClinicalTrials.gov · Last updated 21 Aug 2026
Brief summary (registry, in English)
Levetiracetam (LEV: (S)-α-ethyl-2-oxo-pyrrolidine acetamide) is an anticonvulsant/antiepileptic drug. The specific aim of this study is to assess the efficacy of low-dose LEV in reducing hippocampal activity in schizophrenia. The investigators also hypothesize that LEV will improve neurocognition in participants with schizophrenia.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 29 Dec 2015
- Start date
- 1 Jun 2013
- Primary completion date
- 30 Sept 2024
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Schizophrenia
- NCT number
- NCT02647437
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 1 Jun 2013 to the primary completion date, 30 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant neurological disorders
Other
- Substance abuse
- Significant head trauma/injury
- Left-handedness
- Pregnancy
- MRI-specific exclusion criteria (e.g., claustrophobia, weight \> 450lbs, metal in the body)
Who the study is looking for
- Diagnosis of schizophrenia or schizoaffective disorder
- Good general health
- Normal vital signs (blood pressure, pulse, cardiac, pulmonary, abdominal, neurological exam)
- Normal renal function (as assessed by a metabolic panel at screening if results current within three months are not already available)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.